InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S.
2024年7月24日 - 9:30AM
ビジネスワイヤ(英語)
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading
biopharmaceutical company focusing on the treatment of cancer and
autoimmune diseases, today announced that the first subject has
been dosed in clinical trial of the Company's novel TYK2 (Tyrosine
Kinase 2) inhibitor ICP-332 in the United States.
ICP-332 is a potent and selective TYK2 inhibitor. ICP-332
achieved multiple efficacy endpoints in the China Phase II study
for the treatment of patients with moderate-to-severe atopic
dermatitis (AD), demonstrating an outstanding efficacy and safety
profile. ICP-332 showed better efficacy profile across different
classes/MoAs of therapies for the treatment of AD patients (not a
head-to-head comparison). The detailed data was presented at the
2024 American Academy of Dermatology (AAD) Annual Meeting as a
late-breaking oral presentation.
Currently, no TYK2 inhibitors have obtained marketing approval
for the treatment of AD anywhere in the world. As a non-receptor
tyrosine kinase, TYK2 is a member of the JAK kinase family, which
is an important kinase on the JAK-STAT signaling pathway and plays
an important role in the pathogenesis of inflammatory diseases.
Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare,
said, "We are committed to developing innovative drugs in the field
of autoimmune diseases. In addition to ICP-332, we have developed
robust pipeline of differentiated therapeutics for autoimmune
disease with significant market potential worldwide, including
orelabrutinib (BTK inhibitor), ICP-488 (TYK2-JH2 inhibitor) and
ICP-923 (IL-17 small molecule inhibitor). Adhering to the core
value of 'Science-driven innovation for the benefit of patients’,
we are committed to accelerating clinical development and look
forward to our innovative drugs benefiting patients with autoimmune
diseases as early as possible."
About InnoCare InnoCare is a commercial stage
biopharmaceutical company committed to discovering, developing, and
commercializing first-in-class and/or best-in-class drugs for the
treatment of cancer and autoimmune diseases with unmet medical
needs in China and worldwide. InnoCare has branches in Beijing,
Nanjing, Shanghai, Guangzhou, Hong Kong, and United States.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240723720665/en/
Media Chunhua Lu 86-10-66609879
chunhua.lu@innocarepharma.com
Investors 86-10-66609999 ir@innocarepharma.com